

John R Teerlink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2168165/publications.pdf>

Version: 2024-02-01

175
papers

13,981
citations

25034

57
h-index

22832

112
g-index

191
all docs

191
docs citations

191
times ranked

11053
citing authors

#	ARTICLE	IF	CITATIONS
1	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2013, 381, 29-39.	13.7	810
2	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.1	630
3	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
4	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	27.0	511
5	Heart failure. <i>Lancet, The</i> , 2017, 390, 1981-1995.	13.7	483
6	Rolofylline, an Adenosine A ₁ Receptor Antagonist, in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 1419-1428.	27.0	473
7	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	2.8	397
8	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet, The</i> , 2009, 373, 1429-1439.	13.7	387
9	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	27.0	381
10	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
11	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	362
12	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	30.7	341
13	Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 103-111.	4.1	337
14	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2009.	7.4	330
15	The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. <i>Lancet, The</i> , 2011, 378, 676-683.	13.7	295
16	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	2.2	276
17	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2016, 388, 2895-2903.	13.7	229
18	Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. <i>Lancet, The</i> , 2011, 378, 667-675.	13.7	226

#	ARTICLE	IF	CITATIONS
19	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
20	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1021-1034.	2.8	211
21	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
22	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	2.8	191
23	Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2245-2252.	2.8	175
24	Effects of Seralixin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	27.0	174
25	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	2.8	159
26	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 185-191.	1.7	157
27	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
28	Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw543.	2.2	148
29	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	7.1	115
30	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 76-87.	3.9	107
31	Seralixin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	7.1	104
32	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	3.9	103
33	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	2.2	102
34	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 329-340.	4.1	100
35	Cardiac Calcitropes, Myotropes, and Mitotropes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2345-2353.	2.8	93
36	Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. <i>European Journal of Heart Failure</i> , 2017, 19, 1520-1529.	7.1	89

#	ARTICLE	IF	CITATIONS
37	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. <i>European Journal of Heart Failure</i> , 2010, 12, 1130-1139.	7.1	88
38	Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. <i>Heart Failure Reviews</i> , 2009, 14, 243-253.	3.9	85
39	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	80
40	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. <i>European Journal of Heart Failure</i> , 2019, 21, 1064-1078.	7.1	79
41	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	4.1	78
42	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	2.9	74
43	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2015, 21, 27-43.	1.7	73
44	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	2.8	73
45	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	7.1	71
46	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	7.1	70
47	Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. <i>American Heart Journal</i> , 2003, 145, S26-S33.	2.7	69
48	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	2.8	69
49	Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): Approaching the asymptote of efficacy?. <i>Journal of Cardiac Failure</i> , 2002, 8, 124-127.	1.7	68
50	Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201.	4.1	68
51	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). <i>American Heart Journal</i> , 2005, 150, 46-53.	2.7	67
52	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , 2015, 21, 179-188.	1.7	65
53	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
54	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	1.6	65

#	ARTICLE	IF	CITATIONS
55	Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. <i>Circulation Research</i> , 2021, 128, 1468-1486.	4.5	63
56	Design of the RELAXin in Acute Heart Failure Study. <i>American Heart Journal</i> , 2012, 163, 149-155.e1.	2.7	60
57	In-hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	7.1	60
58	Sodium-glucose cotransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. <i>European Journal of Heart Failure</i> , 2021, 23, 826-834.	7.1	60
59	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	6.1	59
60	Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. <i>Cardiology</i> , 2011, 119, 96-105.	1.4	56
61	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	1.7	53
62	Overview of Randomized Clinical Trials in Acute Heart Failure Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 59-67.	1.6	50
63	Agents with vasodilator properties in acute heart failure. <i>European Heart Journal</i> , 2017, 38, 317-325.	2.2	50
64	Impact of Autonomic Regulation Therapy in Patients with Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005879.	3.9	50
65	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1298-1314.	7.1	50
66	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	4.1	49
67	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , 2016, 18, 1041-1050.	7.1	49
68	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 109-118.	7.1	48
69	Treatment with 24-hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1684-1693.	7.1	48
70	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	7.1	47
71	Ivabradine in heart failure—no paradigm SHIFT yet. <i>Lancet, The</i> , 2010, 376, 847-849.	13.7	45
72	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	7.1	45

#	ARTICLE	IF	CITATIONS
73	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	4.1	44
74	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. <i>Stroke</i> , 2016, 47, 2031-2037.	2.0	44
75	Patient-Reported Outcomes in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 791-804.	4.1	41
76	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. <i>ESC Heart Failure</i> , 2020, 7, 76-84.	3.1	41
77	Ivabradine. <i>Circulation</i> , 2016, 133, 2066-2075.	1.6	40
78	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	1.7	38
79	Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 117-127.	4.1	37
80	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	35
81	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	1.7	35
82	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	2.8	35
83	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	1.7	34
84	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	7.1	34
85	Worsening renal function in acute heart failure in the context of diuretic response. <i>European Journal of Heart Failure</i> , 2022, 24, 365-374.	7.1	34
86	Drug Layering in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 775-783.	4.1	32
87	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. <i>European Journal of Heart Failure</i> , 2014, 16, 1362-1371.	7.1	28
88	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). <i>European Journal of Heart Failure</i> , 2017, 19, 739-747.	7.1	28
89	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	4.1	28
90	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , 2016, 22, 815-822.	1.7	27

#	ARTICLE	IF	CITATIONS
91	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018, 107, 170-181.	3.3	27
92	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.8	26
93	Cognitive Decline Over Time in Patients With Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1042-1053.	4.1	26
94	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	4.1	26
95	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021, 23, 567-577.	7.1	26
96	<sc>CHA₂</sc>₂</sub><sc>VASC</sc> score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. <i>European Journal of Heart Failure</i> , 2016, 18, 1261-1266.	7.1	25
97	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. <i>ESC Heart Failure</i> , 2018, 5, 800-808.	3.1	25
98	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053.	1.6	24
99	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	7.1	24
100	The significance of left ventricular ejection time in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 541-551.	7.1	24
101	Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 465-490.	1.8	23
102	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020, 22, 2175-2186.	7.1	23
103	Cardiopietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. <i>ESC Heart Failure</i> , 2020, 7, 3345-3354.	3.1	23
104	Serelaxin and acute heart failure. <i>Heart</i> , 2016, 102, 95-99.	2.9	22
105	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	1.8	22
106	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	3.1	22
107	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
108	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 539-546.	3.0	22

#	ARTICLE	IF	CITATIONS
109	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	3.9	21
110	Patient and Facility Variation in Costs of VA Heart Failure Patients. <i>JACC: Heart Failure</i> , 2016, 4, 551-558.	4.1	21
111	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	7.1	21
112	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	2.8	21
113	Systolic blood pressure reduction during the first 24h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018, 20, 317-322.	7.1	20
114	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1022-1031.	7.1	20
115	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. <i>JAMA Cardiology</i> , 2022, 7, 540.	6.1	20
116	Lung ultrasound: a B-line™ to the prediction of decompensated heart failure. <i>European Heart Journal</i> , 2016, 37, 1252-1254.	2.2	19
117	Mind the Gap: Current Challenges and Future State of Heart Failure Care. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1434-1449.	1.7	19
118	Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. <i>Journal of Cardiac Failure</i> , 2017, 23, 63-71.	1.7	17
119	Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 240-249.	7.1	17
120	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	4.1	17
121	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	3.3	16
122	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 866-874.	1.7	16
123	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>PLoS ONE</i> , 2014, 9, e113447.	2.5	15
124	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	15
125	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , 2020, 8, 961-972.	4.1	15
126	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016.	2.2	15

#	ARTICLE	IF	CITATIONS
127	The role of endothelin in the pathogenesis of heart failure. <i>Current Cardiology Reports</i> , 2002, 4, 206-212.	2.9	14
128	Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
129	Late breaking heart failure trials from the 2003 ACC meeting: EPHEBUS and COMPANION. <i>Journal of Cardiac Failure</i> , 2003, 9, 158-163.	1.7	13
130	Haemodynamic effects of the nitroxyl donor cimlanod (<sc>BMS</sc>â€986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.	7.1	13
131	Inotropic therapies in heart failure and cardiogenic shock: an educational review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 676-686.	1.0	13
132	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	4.1	12
133	Reversal of left ventricular remodeling: Role of the endothelin pathway. <i>Journal of Cardiac Failure</i> , 2002, 8, S494-S499.	1.7	11
134	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	1.7	11
135	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	11
136	What's Next for Acute Heart Failure Research?. <i>Academic Emergency Medicine</i> , 2018, 25, 85-93.	1.8	11
137	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	7.1	11
138	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2016, 23, 922-931.	1.8	10
139	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	2.7	10
140	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e008007.	3.9	10
141	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <sc>RELAXâ€AHF</sc>â€2 study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	7.1	10
142	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (<sc>COSMIC</sc>â€<sc>HF</sc>). <i>European Journal of Heart Failure</i> , 2021, 23, 1052-1056.	7.1	10
143	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 2212-2220.	2.2	10
144	Team-based Care for Patients Hospitalized with Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 359-370.	2.1	9

#	ARTICLE	IF	CITATIONS
145	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1561-1570.	7.1	9
146	Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007814.	3.9	9
147	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 857538.	2.8	9
148	Screening for Sleep-Disordered Breathing in Patients Hospitalized for Heart Failure —. <i>JACC: Heart Failure</i> , 2015, 3, 732-733.	4.1	8
149	The safety of sacubitril-valsartan for the treatment of chronic heart failure. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 257-263.	2.4	8
150	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e022288.	3.7	8
151	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
152	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. <i>American Journal of Cardiology</i> , 2015, 116, 904-912.	1.6	7
153	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. <i>ESC Heart Failure</i> , 2019, 6, 297-307.	3.1	7
154	Challenges and Potential Improvements to Patient Access to Pharmaceuticals. <i>Circulation</i> , 2020, 142, 790-798.	1.6	7
155	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	1.7	7
156	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	4.1	7
157	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008594.	3.9	7
158	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019, 7, 913-921.	4.1	6
159	Heart Failure Site-Based Research in the United States. <i>JACC: Heart Failure</i> , 2019, 7, 431-438.	4.1	6
160	the Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 812.	1.7	5
161	Systolic time intervals in patients with heart failure: time to teach new dogs old tricks. <i>European Journal of Heart Failure</i> , 2020, 22, 1183-1185.	7.1	5
162	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2016, 22, 618-627.	1.7	4

#	ARTICLE	IF	CITATIONS
163	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. JACC: Heart Failure, 2018, 6, 298-307.	4.1	4
164	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). American Journal of Cardiology, 2018, 122, 821-827.	1.6	3
165	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation: Heart Failure, 2021, 14, e007759.	3.9	3
166	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009199.	3.9	3
167	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients. JACC: Heart Failure, 2017, 5, 603-610.	4.1	2
168	Patient-Reported Outcome Instruments in Heart Failure. JACC: Heart Failure, 2018, 6, 561-563.	4.1	2
169	Assessing the lifetime benefit of heart failure therapies. Lancet, The, 2020, 396, 75-77.	13.7	2
170	Cardiac myosin activators: up and coming. European Journal of Heart Failure, 2015, 17, 750-752.	7.1	1
171	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. American Heart Journal, 2021, 240, 73-80.	2.7	1
172	Mind or Body. Archives of Internal Medicine, 2011, 171, 758-9.	3.8	0
173	Serelaxin in the Treatment of Acute Heart Failure. Current Emergency and Hospital Medicine Reports, 2016, 4, 213-218.	1.5	0
174	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. Heart Failure Reviews, 2021, 26, 255-262.	3.9	0
175	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. Circulation, 2015, 132, .	1.6	0